New Study Reveals Glaucoma Treatment Trends and Health Inequalities in New Zealand
A new 10-year study has highlighted important trends in how glaucoma is treated across New Zealand. The research shows that latanoprost, a common eye drop medication, is now the most frequently prescribed treatment, accounting for 40% of all glaucoma prescriptions in the country.
Glaucoma is a serious eye condition that can lead to permanent vision loss if it is not managed correctly. The study analyzed data over a decade to understand how patients are accessing care and which medications are being used most often by eye specialists.
However, the report also identifies significant concerns regarding health equity. The findings show that there are persistent disparities in treatment rates for Māori and Pasifika patients. These groups continue to face greater challenges in receiving consistent care compared to other populations in New Zealand.
Health experts suggest that these gaps in treatment are a priority for the medical community. Addressing these inequalities is essential to ensure that all New Zealanders, regardless of their background, have equal access to sight-saving treatments.
Moving forward, the study encourages healthcare providers to focus on improving access to eye care services for underserved communities. By identifying these gaps, the health sector hopes to create more effective strategies to protect the vision of all New Zealanders.